CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Eteplirsendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02286947
NCT02286947Phase 2Completed
CompareCT.gov

An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.·interventional·Posted Nov 10, 2014·Updated Mar 30, 2020

In Brief

A Phase 2 clinical trial evaluating Eteplirsen for Muscular Dystrophy, Duchenne. Completed, enrolled 24 participants across 9 sites.

Detailed Summary

The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscular Dystrophy, Duchenne
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 10, 2014
Enrollment StartNov 1, 2014
Primary CompletionApr 21, 2017
Study CompletionMar 23, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.6 years ago

Interventions

Eteplirsendrug

Eteplirsen solution for IV infusion